Disc Medicine (NASDAQ:IRON) COO Jonathan Yen-Wen Yu Sells 8,796 Shares

Disc Medicine, Inc. (NASDAQ:IRON) COO Jonathan Yen-Wen Yu sold 8,796 shares of Disc Medicine stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $83.12, for a total value of $731,123.52. Following the completion of the sale, the chief operating officer owned 54,324 shares of the company’s stock, valued at $4,515,410.88. This trade represents a 13.94% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Jonathan Yen-Wen Yu also recently made the following trade(s):

• On Monday, August 24th, Jonathan Yen-Wen Yu sold 300 shares of Disc Medicine stock. The stock was sold at an average price of $82.53, for a total transaction of $24,759.00.
• On Wednesday, August 12th, Jonathan Yen-Wen Yu sold 804 shares of Disc Medicine stock. The shares were sold at an average price of $82.64, for a total transaction of $66,442.56.
• On Tuesday, July 7th, Jonathan Yen-Wen Yu sold 100 shares of Disc Medicine stock. The stock was sold at an average price of $82.50, for a total transaction of $8,250.00.
• On Friday, June 26th, Jonathan Yen-Wen Yu sold 300 shares of Disc Medicine stock. The shares were sold at an average price of $72.50, for a total transaction of $21,750.00.
• On Monday, June 22nd, Jonathan Yen-Wen Yu sold 9,700 shares of Disc Medicine stock. The shares were sold at an average price of $72.66, for a total transaction of $704,802.00.
• On Tuesday, June 16th, Jonathan Yen-Wen Yu sold 18,612 shares of Disc Medicine stock. The stock was sold at an average price of $69.19, for a total value of $1,287,764.28.

Disc Medicine Price Performance

Shares of Disc Medicine stock opened at $82.67 on Thursday. The business’s fifty day moving average price is $76.56 and its 200 day moving average price is $69.95. Disc Medicine, Inc. has a twelve month low of $40.00 and a twelve month high of $99.50. The company has a current ratio of 24.14, a quick ratio of 24.14 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $316.63 million, a P/E ratio of -12.56 and a beta of 1.00.

Disc Medicine (NASDAQ:IRON) last released its quarterly earnings data on Thursday, July 30th. The company reported ($1.54) EPS for the quarter, topping analysts’ consensus estimates of ($1.71) by $0.17. As a group, research analysts anticipate that Disc Medicine, Inc. will post -6.61 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on IRON shares. Morgan Stanley reiterated an “overweight” rating and set a $90.00 price objective on shares of Disc Medicine in a research note on Monday, August 17th. HC Wainwright raised their target price on shares of Disc Medicine from $118.00 to $120.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Wall Street Zen raised shares of Disc Medicine from a “sell” rating to a “hold” rating in a research note on Saturday, August 1st. Weiss Ratings restated a “sell (d-)” rating on shares of Disc Medicine in a report on Friday, July 17th. Finally, Wedbush reaffirmed an “outperform” rating and set a $88.00 price target on shares of Disc Medicine in a research report on Wednesday, June 10th. Ten analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $106.50.

Hedge Funds Weigh In On Disc Medicine

Several hedge funds and other institutional investors have recently bought and sold shares of IRON. State of Wyoming acquired a new stake in Disc Medicine in the second quarter valued at approximately $25,000. ANTIPODES PARTNERS Ltd purchased a new stake in shares of Disc Medicine during the fourth quarter valued at approximately $33,000. Allworth Financial LP acquired a new position in shares of Disc Medicine during the second quarter worth $46,000. Nykredit A S acquired a new position in shares of Disc Medicine during the second quarter worth $103,000. Finally, Persistent Asset Partners Ltd acquired a new position in shares of Disc Medicine during the fourth quarter worth $141,000. 83.70% of the stock is owned by institutional investors and hedge funds.

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.